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Abstract
Purpose The aim of this study was to evaluate the potential of
hair analysis to monitor medication adherence in headache
patients undergoing chronic therapy. For this purpose, the fol-
lowing parameters were analyzed: the detection rate of 23
therapeutic drugs in headache patients’ hair, the degree of
agreement between the self-reported drug and the drug found
in hair, and whether the levels found in hair reflected the drug
intake reported by the patients.
Methods The study included 93 patients suffering from pri-
mary headaches declaring their daily intake of at least one of
the following drugs during the 3 months before the hair sam-
pling: alprazolam, amitriptyline, citalopram, clomipramine,
clonazepam, delorazepam, diazepam, duloxetine, fluoxetine,
flurazepam, levomepromazine, levosulpiride, lorazepam,
lormetazepam, mirtazapine, paroxetine, quetiapine, sertraline,
topiramate, trazodone, triazolam, venlafaxine, and zolpidem.
A detailed pharmacological history and a sample of hair
were collected for each patient. Hair samples were analyzed
by liquid chromatography-electrospray tandem mass spec-
trometry, using a previously developed method.
Results All 23 drugs were detected in the examined hair sam-
ples. The agreement between the self-reported drug and the
drug found in hair was excellent for most analytes (P < 0.001,
Cohen’s kappa); a statistically significant relationship
(P < 0.05, linear regression analysis) between dose and hair
level was found for amitriptyline, citalopram, delorazepam,
duloxetine, lorazepam, and venlafaxine.
Conclusions Hair analysis proved to be a unique matrix to
document chronic drug use in headache patients, and the level
found for each individual drug can represent a reliable marker
of adherence to pharmacological treatments.
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Introduction
Primary headaches are recurrent chronic disorders and highly
prevalent: for example, in Europe, 53% of adults suffer from
headache [1]. These disorders are debilitating, reduce the
quality of life, and have enormous social costs and no
resolutive cure [2]. Pharmacological treatments are the main
tools to manage them. When acute headache episodes are
frequent, a prophylactic treatment is indicated. If prophylaxis
is to be effective, drugs are required to be taken daily for 3–
6 months, independently from the occurrence of the attacks
[3]. Moreover, headache patients often suffer from psychiatric
comorbidities that aggravate the headache and require
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prolonged pharmacological treatments [4]. Unfortunately, be-
tween 25 and 50% of headache patients are not compliant with
their pharmacological treatment; this fact represents a critical
problem, since non-adherent patients fail to benefit from the
prescribed therapy [5]. The problem is compounded by the
fact that no tools are available in clinical practice to monitor
headache patients’ adherence to long term treatments.
In recent years, various analytical protocols have been de-
veloped for a sensitive determination of drugs and related
metabolites in hair samples, especially in the forensic field.
Hair analysis could therefore represent an important tool also
for therapeutic drug monitoring [6]. In spite of the large num-
ber of potentially determinable xenobiotics, the reported pro-
cedures only focused on the analysis of few therapeutic drugs,
in a limited number of forensic cases, mostly on autopsy sam-
ples of hair belonging to subjects with unknown therapy
(doses and length of treatment) [7, 8]. As a matter of fact, hair
analysis as a tool for therapeutic drug monitoring has not
received much attention in the clinical field, despite its poten-
tial usefulness, due to the noninvasive sampling technique, the
wide detection window, and the possibility to determine si-
multaneously various analytes in the same sample [9, 10].
The goal of this study was to evaluate the usefulness of hair
analysis in documenting headache patients’ adherence to
chronic treatments. We therefore analyzed the detection rate
of 23 therapeutic drugs in headache patients’ hair, the degree
of agreement between the self-reported drug and the type of
drug found in hair, and whether the concentrations measured
in hair reflected the drug doses that the patients had reported to
have taken in the previous 3-month period.
Patients and methods
Patients
This study is part of a research project concerning the analysis
of therapeutic drugs in the hair of 300 primary headache pa-
tients consecutively afferent to a headache center. Only pa-
tients with a minimum occipital scalp hair length of 4 cmwere
enrolled in the study; patients who did not understand both the
purpose and the protocol of the study were excluded. The
patients were enrolled and hair specimens were collected from
October 1, 2013 to December 23, 2014.
In this study we included 93 primary headache patients
(mean age ± SD: 48.13 ± 12.03 years; females 94 %) who
had reported to be in daily treatment, for at least 3 months, for
headache prophylaxis or for their psychiatric comorbidities,
with at least one of the following 23 drugs: alprazolam, ami-
triptyline, citalopram, clomipramine, clonazepam,
delorazepam, diazepam, duloxetine, fluoxetine, flurazepam,
levomepromazine, levosulpiride, lorazepam, lormetazepam,
mirtazapine, paroxetine, quetiapine, sertraline, topiramate,
trazodone, triazolam, venlafaxine, and zolpidem. All demo-
graphic and diagnosis data are available as a supplementary
table.
Procedures
For each patient, demographic data, hair characteristics, head-
ache diagnosis, and a detailed pharmacological history (type
of the drug taken, daily dose, and treatment duration) relative
to the previous 3 months were collected. Drug quantities for
each drug were converted in mg taken in 3 months.
According to the international guidelines for hair analysis
[11], a hair sample of at least 7 mm in diameter and 4 cm in
length was taken from each patient’s nuchal area. From each
hair sample we cut and analyzed a single section measuring
3 cm, proximal, i.e., near the scalp, to cover the previous
3 months.
The extraction and purification of the samples were per-
formed according to Licata et al. [12]. After decontamination
and trituration, hair samples (50 mg aliquot) were added with
2.0 mL methanol and 20 μL of the IS solution and sonicated
overnight at 45 °C; after addition of the roQ dSPE
QuEChERS sorbent kit (2.0 mL, 150 mg MgSO4, 50 mg
PSA-Primary Secondary Amine, 50 mg endcapped C18,
Phenomenex, Torrance, CA, USA), the tubes were vortexed
and centrifuged. One milliliter of each purified supernatant
was evaporated to dryness and reconstituted in 200 μL of
the LC mobile phase. The purified hair extracts were then
subjected to LC-MS/MS analysis (injection volume, 10 μL)
on a Kinetex® Biphenyl column under the gradient elution
conditions. The method had been developed by us and vali-
dated [12] according to the model proposed by the Scientific
World Group for Forensic Toxicology in 2013, in standard
practices for method validation in forensic toxicology [11].
Experimental details concerning LC-MS/MS analysis and
method validation have been reported in a previous paper
[12] and are briefly summarized as an online supplementary
document.
A number was assigned to each authentic hair sample, and
the laboratory made blind assessments.
Quantitative analyses of the drugs were performed on the
basis of the calibration curves daily prepared and analyzed as
reported [12].
Data and statistical analysis
A descriptive analysis of all variables was conducted as
far as the following aspects were concerned: demo-
graphic characteristics, headache diagnosis, and pharma-
cological history.
Statistical analysis was carried out by the StataIC 13 soft-
ware. The continuous variables normally distributed were
expressed as mean ± standard deviation. The agreement
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between the type of drug reported by the patient and the one
detected in hair was evaluated by Cohen’s K coefficient. For
the drugs taken by at least five patients, the relationship be-
tween the reported cumulative dose (mg/3 months) and the
corresponding drug hair levels was calculated by univariate
linear regression analysis. P < 0.05 was chosen as significant
for all the tests.
Results
All 23 drugs (Table 1) were successfully identified in
the examined hair samples: 82% of the parent drug (19/
23) was found in 100% of patients declaring their in-
take in the previous 3 months. Only few hair samples
resulted negative for the self-reported drug: amitriptyline
(five hair samples), delorazepam (one hair sample), par-
oxetine (two hair samples), and venlafaxine (one hair
sample). The agreement between the type of drug re-
ported by the patient and the one detected in hair,
analyzed by Cohen’s kappa, was statistically significant
for all drugs (P < 0.001) and excellent (>0.8) for most
of them. Nine hair samples were also positive for not
declared drugs: citalopram, three hair samples; clomip-
ramine, one hair sample; mirtazapine, two hair samples;
sertraline, one hair sample; and zolpidem, two hair
samples.
Cumulative doses for the same drug taken by patients
during the examined period (Table 2) differed consider-
ably, leading to high SD values for this variable and to
even higher SD values for hair levels found.
The relationship between cumulative doses and the
levels found (Fig. 1), analyzed for the drugs positive
in at least five patients, was statistically significant
(P < 0.05, linear regression analysis) for amitriptyline,
citalopram, delorazepam, duloxetine, lorazepam, and
venlafaxine.
Considering the relationship between doses and hair levels
and the calculated regression curve, the drug hair incorpora-
tion tendency was, in decreasing order, citalopram >
Table 1 Hair analysis results and
agreement between the self-
reported drug and drug found in
hair samples. The 93 enrolled pa-
tients self-reported a chronic
treatment with at least one of the
target drugs during the 3 months
preceding the hair sampling;
some patients reported the intake
of more than one drug during the
examined time period
Self-reported drug Number of positive
hair samples (%)
Number of negative
hair samples (%)
Number of patients self-
reporting the drug
Kappa*
Alprazolam 7 (100) 0 7 1.0000a
Amitriptyline 24 (83) 5 (17) 29 0.8649a
Citalopram 16 (100) 0 16 0.8946a
Clomipramine 3 (100) 0 3 0.8517a
Clonazepam 1 (100) 0 1 1.0000a
Delorazepam 22 (96) 1 (4) 23 0.9707a
Diazepam 3 (100) 0 3 1.0000a
Duloxetine 16 (100) 0 16 1.0000a
Fluoxetine 4 (100) 0 4 1.0000a
Flurazepam 1 (100) 0 1 1.0000a
Levomepromazine 1 (100) 0 1 1.0000a
Levosulpiride 4 (100) 0 4 1.0000a
Lorazepam 7 (100) 0 7 1.0000a
Lormetazepam 1 (100) 0 1 1.0000a
Mirtazapine 2 (100) 0 2 0.6568b
Paroxetine 4 (67) 2 (33) 6 0.7891b
Quetiapine 2 (100) 0 2 1.0000a
Sertraline 4 (100) 0 4 0.8833a
Topiramate 12 (100) 0 12 1.0000a
Trazodone 1 (100) 0 1 1.0000a
Triazolam 1 (100) 0 1 1.0000a
Venlafaxine 6 (86) 1 (14) 7 0.9173a
Zolpidem 2 (100) 0 2 0.6568b
Total 144 (94) 9 (6) 153
*All P values <0.001
aKappa values from 0.8 to 1 = excellent agreement
b Kappa values from 0.6 to 0.8 = good agreement
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duloxetine > lorazepam > amitriptyline > venlafaxine >
delorazepam.
Discussion
A fundamental requirement to employ hair analysis in
drug monitoring is that the drugs are incorporated into
the hair. Our results (Table 1) indicate that all 23 differ-
ent therapeutic drugs daily taken at the doses indicated
for headache prophylaxis or the treatment of psychiatric
comorbidities could be determined in the keratin matrix.
These drugs have in fact chemical characteristics, such as
some degree of lipophilicity and basicity, enabling them
to diffuse and be incorporated preferentially into the hair
where the pH is acidic (about 4) [9]. Therefore, this
matrix was a biological specimen suitable to analyze
the concentration of these therapeutic drugs. In addition,
the keratin matrix offers the possibility to determine
simultaneously a large number of drugs in a unique sam-
ple [6] , p lay ing a crucia l ro le in the case of
polymedicated headache patients; in our series, 58 and
36% of the patients self-reported respectively two and
three or more different types of drugs.
Medication adherence is critical to achieve the benefit of
the cure and should be monitored [5]. To measure adherence
to treatment, indirect methods, such as diaries or self-report,
and direct ones, such as quantitative determination of the
drugs in blood or urine, are available. The first overestimates
the adherence, while the routine laboratory methods have a
limited detection window, hours, at most days prior to sam-
pling [13]. To verify adherence during prolonged treatments,
several samples would need to be collected, causing excessive
discomfort to patients. In addition, medications prescribed to
headache patients are often not detected with traditional ana-
lytical methods.
Overall, there was a substantial concordance between the
types of drugs self-reported by the patients and those detected
Table 2 Cumulative doses self-
reported by the 93 patients in the
previous 3 months and hair con-
centrations for the 23 drugs
Self-reported drug (n) Cumulative doses
(mean ± SD, mg)
Hair concentrations
(mean ± SD, pg/mg)
r P value
Alprazolam (7) 41.82 ± 44.09 66.95 ± 65.70 0.5339 0.431
Amitriptyline (24) 1877.50 ± 2218.01 2798.10 ± 3391.70 0.7485 0.015*
Citalopram (16) 1760.63 ± 868.18 2563.88 ± 1906.90 1.6653 <0.001**
Clomipramine (3) 6956.70 ± 11,513.30 3730.00 ± 3516.37
Clonazepam (1) 90.00 90.00
Delorazepam (22) 235.86 ± 395.16 150.26 ± 330.10 0.2563 <0.000**
Diazepam (3) 110.00 ± 43.59 1033.33 ± 1280.80
Duloxetine (16) 4224.40 ± 1608.80 8520.75 ± 7627.80 1.2657 <0.001**
Fluoxetine (4) 2700.00 ± 1800 20,578.25 ± 22,440.20
Flurazepam (1) 1350 359.00
Levomepromazine (1) 2250.00 1037.00
Levosulpiride (4) 2163.00 ± 3101.09 254.75 ± 217.40
Lorazepam (7) 241.07 ± 298.13 263.71 ± 299.30 0.9995 <0.001**
Lormetazepam (1) 180.00 1207.00
Mirtazapine (2) 2700.00 ± 1909.19 586.50 ± 227.90
Paroxetine (4) 1350.00 ± 492.95 804.83 ± 709.90
Quetiapine (2) 506.30 ± 79.50 470.40 ± 508.00
Sertraline (4) 5812.50 ± 3986.30 24,600.25 ± 28,087.20
Topiramate (12) 4774.17 ± 5343.41 2414.17 ± 2028.90 0.2210 0.217
Trazodone (1) 900.00 6379.00
Triazolam (1) 22.50 16.00
Venlafaxine (6) 6750.00 ± 6161.88 1864.14 ± 2174.90 0.3054 0.012*
Zolpidem (2) 2475.00 ± 2863.78 1718.00 ± 1750.80
Linear regression analysis for drugs taken by at least five patients
r slope value
*P < 0.05
**P < 0.01
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by hair analysis. Indeed, 82% of the drugs were found in
100% of the samples of patients who had self-reported them.
The agreement, analyzed by Cohen’s kappa, was statistically
significant (P < 0.01) for all drugs and excellent (kappa >0.8)
for most of them (87%). However, a certain degree of
nonadherence was present: nine samples were negative for
the self-reported drug and nine were positive for unreported
drugs. We hypothesized that these results depended on pa-
tients’ mistakes or forgetfulness rather than on shortcomings
of the previously validated analytical method [12].
The patients (Table 2) had taken different therapeutic
doses, and the respective concentrations of the drugs in hair
presented even greater interindividual variations, as shown by
high standard deviation values. In order to interpret these data,
the factors affecting drug concentrations in hair must be taken
into account. Three factors are fundamental: (1) the individual
characteristics of hair, such as color, cosmetic treatments, and
growth rates ranging from 0.6 to 1.42 cm/month; (2) the in-
terindividual variation in the kinetics of individual drugs,
which affects circulating concentrations and therefore the pen-
etration into growing hair from the bloodstream; (3) the chem-
ical–physical characteristics of the drugs: increased lipophilic-
ity and basicity and lower polarity and molecular weight fa-
cilitate the incorporation into the hair. Despite the mentioned
variability, we found (Fig. 1) a statistically significant relation-
ship between the doses taken and the corresponding concen-
trations in hair for most drugs self-reported by an adequate
number of patients. On the basis of the regression line,
citalopram and duloxetine, both very basic and lipophilic
(the first has pKa 9.78 and logP 3.5 and the second pKa 9.7
and logP 4.72 [14]), were the best incorporated into the keratin
matrix. Other studies, also carried out in the clinical setting,
did not find a statistically significant relationship between dai-
ly dose and hair concentrations [15, 16]. However, these
Fig. 1 Relationship between cumulative dose of the drugs taken in the previous 3months and their concentration in hair [diamond data points, line linear
regression; the fitted line has only been reported when the regression coefficient was statistically significant (P < 0.05); r = slope value]
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studies enrolled psychiatric patients or subjects in palliative
care whose reliability on the medications taken was limited, as
reported by the authors [15, 16]. In our research, the pharma-
cological history of each patient had been collected with ex-
treme attention, although the study was not conducted in a
setting of controlled drug administration.
The relationship between doses taken and measured hair
concentrations was not statistically significant for topiramate,
despite the number of patients who reported its intake. This
result could depend on the considerable interindividual varia-
tions in the kinetics of this drug. In fact, the relationship be-
tween dose and plasma concentration is not linear [17] and
serum concentrations of topiramate show considerable inter-
individual variations for the same administered dose [18].
Our study had some limits. The sample was not large, had a
female prevalence, was intentionally heterogeneous for the
types and doses of the drugs, and was also heterogeneous
for hair color and evidence of cosmetic treatments, in order
to assess the applicability and potentialities of hair analysis in
various clinical situations. Moreover, it was possible to ana-
lyze the relationship between dose and concentration only for
drugs taken by an adequate number of patients.
There is much research focused on the identification of
drugs of abuse in the keratin matrix; however, that dealing
with therapeutic drugs is rather scarce. We could not find
published data on hair levels for duloxetine, levosulpiride,
mirtazapine, paroxetine, and topiramate, and we could not
therefore make comparisons. For the other drugs, measured
concentrations were in agreement with literature, but the lack
of information on the doses and duration of the treatments in
published studies prevents precise comparisons [19–23].
By providing data on the doses and the related concentra-
tions in clinical setting, our study could be a reference to
attribute value to hair levels of the same drugs when the doses
taken are unknown, for example in forensic toxicology.
Conclusions
The results of our study indicated that hair analysis could be a
valuable tool to document the adherence to prescribed thera-
peutic drugs in headache patients. The management of prima-
ry headaches is based solely on clinical history and patient
reports [3]. In such situation, the concentration of drugs mea-
sured in hair represents a reliable marker of intake in the pre-
vious months. This information can help clinical and thera-
peutic decisions.
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